Group 1: International Expansion - The company has established a marketing network covering over 60 countries and regions, enhancing its international presence through participation in industry exhibitions and targeted channel development [3] - The company is actively pursuing international certifications for multiple products to boost global brand recognition [4] - The partnership with Coherent is expected to accelerate market penetration and brand internationalization in the dairy sector [8] Group 2: Financial Performance - In Q3 2025, the company achieved a revenue of 186 million yuan, a year-on-year increase of 17.45% [4] - The net profit attributable to shareholders reached 18.02 million yuan, a significant increase of 362.49% year-on-year [4] - Non-recurring gains and losses impacted net profit by approximately 14.29 million yuan, primarily from asset disposals and government subsidies [4] Group 3: Pet Business Development - The company plans to expand its pet business into areas such as elderly disease prevention and pet consumption, building a diversified business ecosystem [5] - The pet diagnostics segment is projected to exceed 13 million yuan in revenue in 2024, indicating strong growth potential [6] Group 4: Strategic Partnerships - The agreement with Coherent, effective from June 16, 2025, sets a sales target of 73.06 million euros (approximately 600.83 million yuan) for the period from 2025 to 2029 [6] - The collaboration is expected to leverage Coherent's extensive customer base and sales network, enhancing the company's market reach [8] Group 5: Product Offerings and Market Solutions - The company provides comprehensive food safety testing solutions across the supply chain, ensuring high-quality standards in various food sectors [8] - The rapid testing technology is applicable to the prepared food industry, offering solutions for detecting mycotoxins, pesticide residues, and other contaminants [8]

Core Viewpoint - The company, EasyReel Bio, is undergoing significant changes due to frequent shareholder reductions and a strategic shift away from its in vitro diagnostic business, which has seen a drastic decline in demand, particularly for respiratory infectious disease testing products [2][7]. Shareholder Reduction - EasyReel Bio's controlling shareholder, EasyReel (Hainan) Venture Capital Co., Ltd., plans to reduce its holdings by up to 11,521,758 shares, representing 2.84% of the total share capital [3] - Other shareholders, EasyDarui and EasyKairui, also plan to reduce their holdings by 288,500 shares (0.07%) and 341,800 shares (0.08%), respectively [3] - If the maximum reduction occurs, the total cash outflow for the shareholders could reach approximately 1.23 million yuan based on the closing price of 10.12 yuan per share on October 13 [3] Business Performance and Strategy Shift - EasyReel Bio's revenue has significantly declined in 2023, with total revenue of 253 million yuan, a year-on-year decrease of 63.01%, and a net loss of 185 million yuan [7] - The in vitro diagnostic business, which once contributed up to 70% of revenue, has seen a drastic reduction in income, dropping to 47.7 million yuan in 2023, a 90.45% decline [7][8] - The company has shifted its focus back to food safety rapid testing and animal diagnostics, with food safety revenue showing a slight increase of 5.29% in 2024 [8] Historical Financial Performance - From 2020 to 2022, EasyReel Bio's revenue grew significantly due to the COVID-19 pandemic, with total revenues of 259 million yuan, 598 million yuan, and 687 million yuan, respectively [6] - The in vitro diagnostic business revenue during this period surged, reaching 499 million yuan in 2022, accounting for 72.71% of total revenue [6] Future Outlook - The company plans to completely phase out its in vitro diagnostic products by 2025, focusing solely on food safety and animal diagnostics [7][8] - Despite a strategic pivot, the company has faced challenges, with non-recurring net profits remaining negative for two and a half years [8][9]

Core Viewpoint - The announcement details the planned share reduction by the controlling shareholder and actual controller of Yirui Biological, which is not expected to significantly impact the company's governance structure or control [1][2]. Group 1: Share Reduction Plan - Yirui (Hainan) Venture Capital Co., Ltd., the controlling shareholder, plans to reduce its holdings by up to 3,531,208 shares, representing 0.88% of the total share capital [1]. - The actual controller, Zhu Hai, intends to reduce his holdings by up to 7,521,390 shares, accounting for 1.87% of the total share capital [1]. - The total planned reduction by both parties does not exceed 3% of the company's total share capital, with specific limits on the number of shares that can be sold within a 90-day period [1]. Group 2: Company Background and Financials - Yirui Biological was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on February 9, 2021, with an initial issuance of 40.86 million shares at a price of 5.31 yuan per share, raising a total of 217 million yuan [2]. - The company has raised a total of 545 million yuan from two fundraising events, with the first round netting 175 million yuan after expenses [3][4]. - The net profit attributable to shareholders for the years 2021, 2022, 2023, and 2024 were 236.51 million yuan, 82.97 million yuan, -184.91 million yuan, and 17.12 million yuan, respectively [4][5]. Group 3: Financial Performance - In 2024, the company's operating revenue is projected to be 224.25 million yuan, a decrease of 11.75% from 2023 [5]. - The net profit attributable to shareholders is expected to increase by 109.26% in 2024, reaching 17.12 million yuan, compared to a loss of 184.91 million yuan in 2023 [5]. - The cash flow from operating activities showed a significant improvement, with a net cash flow of 34.26 million yuan in 2024, compared to a negative cash flow of -37.25 million yuan in 2023, marking a 191.97% increase [5].

Core Viewpoint - The share reduction plan by major shareholders of Yirui Biological has been completed, resulting in a total cash-out of approximately 8.83 million yuan from the sales of shares [1][2]. Shareholder Reduction Summary - Yirui Biological's major shareholders, Yidari and Yikairei, executed their share reduction plans, with Yidari reducing 411,200 shares (0.1025% of total shares) and Yikairei reducing 575,700 shares (0.1435% of total shares) [1][3]. - Yidari's share reduction occurred through concentrated bidding and block trading, with an average price of 9.33 yuan per share for 116,200 shares and 8.76 yuan per share for 295,000 shares [3]. - Yikairei's share reduction also involved concentrated bidding and block trading, with an average price of 9.30 yuan per share for 275,700 shares and 8.66 yuan per share for 300,000 shares [3]. Shareholder Equity Changes - Shareholder Wang Tianyi reduced his holdings by 6,337,700 shares (1.5792% of total shares) from April 25 to June 6, 2025, bringing his total holdings down to 20,065,821 shares (4.999984% of total shares) [2][4]. - Wang Tianyi's reduction means he is no longer a major shareholder with over 5% ownership [2][4]. Company Financial Activities - Yirui Biological raised a total of 217 million yuan during its IPO, with a net amount of 175 million yuan after deducting issuance costs [6]. - The company issued convertible bonds worth 328.2 million yuan in August 2023, which began trading on September 6, 2023 [7].